Research programme: dengue fever virus vaccine - GenVec/Naval Medical Research Center

Drug Profile

Research programme: dengue fever virus vaccine - GenVec/Naval Medical Research Center

Alternative Names: Dengue fever vaccine - GenVec

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GenVec; Naval Medical Research Center
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dengue

Most Recent Events

  • 16 Jun 2017 GenVec was acquired by Intrexon Corporation
  • 28 Mar 2014 Discontinued for Dengue in USA (Parenteral) before 28 March 2014
  • 25 Jan 2011 GenVec establishes CRADA with US Naval Medical Research Center for the development of Dengue fever virus vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top